Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 212

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer

Open access
Lu, Haonan, Arshad, Mubarik, Thornton, Andrew, Avesani, Giacomo, Cunnea, Paula, Curry, Ed, Kanavati, Fahdi, Liang, Jack, Nixon, Katherine, Williams, Sophie T., Hassan, Mona Ali, Bowtell, David D. L., Gabra, Hani, Fotopoulou, Christina, Rockall, Andrea, Aboagye, Eric O. · 2019 · Nature Communications

Abstract

The five-year survival rate of epithelial ovarian cancer (EOC) is approximately 35–40% despite maximal treatment efforts, highlighting a need for stratification biomarkers for personalized treatment. Here we extract 657 quantitative mathematical descriptors from the preoperative CT images of 364 EOC patients at their initial presentation. Using machine learning, we derive a non-invasive summary-statistic of the primary ovarian tumor based on 4 descriptors, which we name “Radiomic Prognostic Vector” (RPV). RPV reliably identifies the 5% of patients with median overall survival less than 2 years, significantly improves established prognostic methods, and is validated in two independent, multi-center cohorts. Furthermore, genetic, transcriptomic and proteomic analysis from two independent datasets elucidate that stromal phenotype and DNA damage response pathways are activated in RPV-stratified tumors. RPV and its associated analysis platform could be exploited to guide personalized therapy of EOC and is potentially transferrable to other cancer types.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-019-08718-9

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 46

  1. Aerts, H. J. The potential of radiomic-based phenotyping in precision edicine: a review. JAMA Oncol. 2, 1636–1642 (2016). · DOI · Paper page
  2. Nougaret, S. et al. High-grade serous ovarian cancer: associations between BRCA mutation status, CT imaging phenotypes, and clinical outcomes. Radiology 285, 472–481 (2017). · DOI
  3. Vargas, H. A. et al. Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. Radiology 274, 742–751 (2015). · DOI
  4. Heinzmann, K., Carter, L. M., Lewis, J. S. & Aboagye, E. O. Multiplexed imaging for diagnosis and therapy. Nat. Biomed. Eng. 1, 697–713 (2017). · DOI · Paper page
  5. Agarwal, R. & Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3, 502–516 (2003). · DOI · Paper page
  6. Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11, 719–725 (2011). · DOI · Paper page
  7. Etemadmoghadam, D. et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin. Cancer Res. 15, 1417–1427 (2009). · DOI · Paper page
  8. Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489–494 (2015). · DOI · Paper page
  9. Verhaak, R. G. et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123, 517–525 (2013).
  10. Leong, H. S. et al. Efficient molecular subtype classification of high-grade serous ovarian cancer. J. Pathol. 236, 272–277 (2015). · DOI
  11. Tothill, R. W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198–5208 (2008). · DOI · Paper page
  12. Bagnoli, M. et al. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study. Lancet Oncol. 17, 1137–1146 (2016). · DOI
  13. Arshad, M. A. et al. Discovery of pre-therapy 2-deoxy-2-(18)F-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. Eur. J. Nucl. Med. Mol. Imaging 46, 455–466 (2019). · DOI
  14. Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011). · DOI · Paper page
  15. Tibshirani, R. The lasso method for variable selection in the Cox model. Stat. Med. 16, 385–395 (1997). · doi:10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3
  16. Harrell, F. E. Jr., Lee, K. L. & Mark, D. B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat. Med. 15, 361–387 (1996). · doi:10.1002/(sici)1097-0258(19960229)15:4<361::aid-sim168>3.0.co;2-4
  17. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518–527 (2008). · DOI · Paper page
  18. Malhotra, D. et al. Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nat. Immunol. 13, 499–510 (2012). · DOI · Paper page
  19. Gaillard, H., Garcia-Muse, T. & Aguilera, A. Replication stress and cancer. Nat. Rev. Cancer 15, 276–289 (2015). · DOI · Paper page
  20. Wei, S. H. et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin. Cancer Res. 12, 2788–2794 (2006). · DOI
  21. Macintyre, G. et al. Copy-number signatures and mutational processes in ovarian carcinoma. bioRxiv https://doi.org/10.1101/174201 (2017). · DOI
  22. Parkinson, C. A. et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 13, e1002198 (2016). · DOI · Paper page
  23. De Fauw, J. et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat. Med. 24, 1342–1350 (2018). · DOI · Paper page
  24. Busuttil, R. A. et al. A signature predicting poor prognosis in gastric and ovarian cancer represents a coordinated macrophage and stromal response. Clin. Cancer Res. 20, 2761–2772 (2014). · DOI
  25. Zhang, S. Z. et al. Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer. Sci. Rep.-Uk 5, 16066 (2015). · DOI
  26. Chen, P. et al. Identification of prognostic groups in high-grade serous ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res. 75, 2987–2998 (2015). · DOI
  27. Chen, J. L. Y. et al. Stromal responses among common carcinomas correlated with clinicopathologic features. Clin. Cancer Res. 19, 5127–5135 (2013). · DOI
  28. Bonome, T. et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 65, 10602–10612 (2005). · DOI · Paper page
  29. Wang, L. M. et al. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 7, 4183–4194 (2016). · DOI
  30. Mo, F. et al. Stromal gene expression is predictive for metastatic primary prostate cancer. Eur. Urol. 73, 524–532 (2018). · DOI
  31. Isella, C. et al. Stromal contribution to the colorectal cancer transcriptome. Nat. Genet. 47, 312–319 (2015). · DOI · Paper page
  32. Frings, O. et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. Am. J. Pathol. 182, 2037–2047 (2013). · DOI
  33. Mhawech-Fauceglia, P. et al. Stromal expression of fibroblast activation protein alpha (FAP) predicts platinum resistance and shorter recurrence in patients with epithelial ovarian cancer. Cancer Microenviron. 8, 23–31 (2015). · DOI · Paper page
  34. Davidson, B., Trope, C. G. & Reich, R. The role of the tumor stroma in ovarian cancer. Front. Oncol. 4, 104 (2014).
  35. Sherman-Baust, C. A. et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3, 377–386 (2003). · DOI · Paper page
  36. Wang, W. et al. Effector T cells abrogate stroma-mediated chemoresistance in ovarian. Cancer Cell. 165, 1092–1105 (2016).
  37. Kristensen, V. N. et al. Principles and methods of integrative genomic analyses in cancer. Nat. Rev. Cancer 14, 299–313 (2014). · DOI · Paper page
  38. Jena, R. et al. A novel algorithm for the morphometric assessment of radiotherapy treatment planning volumes. Br. J. Radiol. 83, 44–51 (2010). · doi:10.1259/bjr/27674581
  39. Cook, G. J. R. et al. Are pretreatment F-18-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J. Nucl. Med. 54, 19–26 (2013). · DOI · Paper page
  40. Cheng, N. M. et al. Textural features of pretreatment F-18-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma. J. Nucl. Med. 54, 1703–1709 (2013). · DOI
  41. Amadasun, M. & King, R. Textural features corresponding to textural properties. IEEE T. Syst. Man Cyb. 19, 1264–1274 (1989). · DOI · Paper page
  42. Cheng, N. M. et al. Zone-size nonuniformity of F-18-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. Eur. J. Nucl. Med. Mol. I 42, 419–428 (2015). · DOI
  43. Hatt, M. et al. F-18-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J. Nucl. Med. 56, 38–44 (2015). · DOI · Paper page
  44. Tibes, R. et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 5, 2512–2521 (2006). · DOI · Paper page
  45. Bell, D. et al. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011). · DOI · Paper page
  46. Yeung, T. L. et al. TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 73, 5016–5028 (2013). · DOI · Paper page

Cited by

See all 212

Metadata

Authors
Lu, H., Arshad, M., Thornton, A., Avesani, G., Cunnea, P., Curry, E., Kanavati, F., Liang, J., Nixon, K., Williams, S. T., Hassan, M. A., Bowtell, D. D. L., Gabra, H., Fotopoulou, C., Rockall, A., & Aboagye, E. O.
Venue
Nature Communications
Published
2019-02-15
Volume
10
Issue
1
Pages
764-764
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2913823430
Cited by
212
References
11
FWCI
16.05
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. https://app.cochat.ai/papers/10.1038/s41467-019-08718-9
The paper
Lu, H., Arshad, M., Thornton, A., Avesani, G., Cunnea, P., Curry, E., Kanavati, F., Liang, J., Nixon, K., Williams, S. T., Hassan, M. A., Bowtell, D. D. L., Gabra, H., Fotopoulou, C., Rockall, A., & Aboagye, E. O. (2019). A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. Nature Communications. https://doi.org/10.1038/s41467-019-08718-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.